



Journal of **COMMERCIAL BIOTECHNOLOGY**

APRIL 2013

VOLUME 19 | NUMBER 2

ISSN: 1462-8732 / eISSN 1478-565X

WWW.COMMERCIALBIOTECHNOLOGY.COM

Journal of COMMERCIAL BIOTECHNOLOGY

VOLUME 19

NUMBER 2

APRIL 2013

Contents

Pharmaceutical companies, faced with growing pricing pressures, should look outside their products for new revenue opportunities <i>G. Steven Burrill</i>	3
Commercial Biotechnology in Mexico <i>Minerva Valdés, Fernando Quezada</i>	6
Defining valuable information in a shifting industry <i>Andrew F Bourgoin</i>	9
Technology transfer: Bridging academic research and society — a communicative approach <i>Martin Vad Bennetzen, Lars Stig Møller</i>	11
The financial ecosystem available to early-stage biotechnology firms and its misalignment with interests of these firms, of the biotechnology industry and with global disease burden <i>Gergely Tóth</i>	17
Developing cell therapies: Enabling cost prediction by value systems modeling to manage developmental risk <i>Mark Joseph McCall, David John Williams</i>	27
A patient centric commercial model for cancer care <i>Sanjay K Rao</i>	40
Challenges and prospects for monoclonal antibodies in China <i>Honghao Shi, Meiwan Chen, Yunzhen Shi, Hao Hu, Yitao Wang</i>	49
A business perspective on IP: Open innovation vs. open source in commercializing biomedical opportunities <i>Arthur A. Boni</i>	56
Getting social with biotechnology business development <i>Tim McCready</i>	61
Bowman v. Monsanto: Revisiting the Exhaustion Doctrine and its application to biotechnology and digital technologies <i>Susan K. Finston</i>	64

Continued ...

While every effort is made to see that no inaccurate data, opinion or statement appears in this journal, the Publishers and the Editors wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor(s) or advertiser(s) concerned. Accordingly, the Publishers, the Editors and their respective employees, officers and agents accept no liability whatsoever for the consequences of such inaccurate or misleading data, opinion or statement.

Should the HHS decision to overrule FDA on Plan B be reversed?
Peter J. Pitts